TY - JOUR
T1 - A beta version of life
T2 - p110β takes center stage.
AU - Dbouk, Hashem A.
AU - Backer, Jonathan M.
PY - 2010/12
Y1 - 2010/12
N2 - The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.
AB - The PI3K pathway is frequently activated in tumors, most commonly through p110α mutation or PTEN deletion. In contrast to p110α, p110β is oncogenic when over-expressed in the wild-type state, suggesting that its regulation by p85 is different than that of p110α. In this perspective, we summarize recent data concerning the regulation of p110β, which shows that wild-type p110β acts like an oncogenic mutant of p110α. We also discuss the significance of this altered regulation in tumor models of PTEN deletion, as well as the potential implications of the unique p110β regulation on GPCR-driven tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=79958016002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958016002&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.207
DO - 10.18632/oncotarget.207
M3 - Review article
C2 - 21321382
AN - SCOPUS:79958016002
SN - 1949-2553
VL - 1
SP - 729
EP - 733
JO - Oncotarget
JF - Oncotarget
IS - 8
ER -